<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974675</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-354-0602</org_study_id>
    <secondary_id>2006-003199-36</secondary_id>
    <nct_id>NCT00974675</nct_id>
  </id_info>
  <brief_title>A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma</brief_title>
  <official_title>A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study includes participants with moderate asthma who were randomly assigned to receive
      the study medication (CAT-354) or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo controlled study. Following confirmation of
      eligibility, subjects with moderate asthma will be recruited sequentially to one of three
      dose groups and randomly assigned within dose group to either CAT-354 or placebo. Doses of
      the assigned treatment will be administered on three occasions 28 days apart. Follow up for
      pharmacokinetic blood sampling and safety will continue to Day 147 post-first dose (91 days
      post-third dose).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354
    10 mg/kg group due to the slow recruitment rate.
  </why_stopped>
  <start_date type="Actual">September 29, 2006</start_date>
  <completion_date type="Actual">August 3, 2007</completion_date>
  <primary_completion_date type="Actual">August 3, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Second Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 28; Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Third Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 56; Day 63, 84, 105 and 147</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - t]) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC[0 - Infinity]) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
    <description>AUC (0 - infinity) = Area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Phase Half-Life (t[1/2]el) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
    <description>Terminal elimination phase half-life is the time measured for the serum concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
    <description>Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Clearance was normalized by the body weight of the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vd) for CAT-354 After First Dose</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Volume of distribution was normalized to the body weight of the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After First Dose</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After Second Dose</measure>
    <time_frame>Pre-dose on Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Concentration for CAT-354 28 Days (C28) After Third Dose</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio (R0) for CAT-354</measure>
    <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0 and 56; Pre-dose on Day 28; Day 4, 7, 14, 21, 63 and 84</time_frame>
    <description>Accumulation ratio is calculated as: R0 = AUC(56 - 84)/AUC(0 - 28) where AUC(0 - 28) and AUC(56 - 84) are the area under the serum concentration time curve over a dosage interval determined after the first dose (Day 0 to Day 28) and after the third dose (Day 56 to Day 84), respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Day 0 to Day 147</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 147 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Moderate Asthma</condition>
  <arm_group>
    <arm_group_label>CAT-354 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-354 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-354 10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAT-354 1mg/kg</intervention_name>
    <description>CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 1 mg/kg</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAT-354 5 mg/kg</intervention_name>
    <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 5 mg/kg</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAT-354 10mg/kg</intervention_name>
    <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 10mg/kg</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or infertile females

          -  Subjects with asthma, well controlled on inhaled corticosteroid and taken as required
             (PRN) short acting beta 2 agonist therapy only

          -  Unchanged dose of inhaled corticosteroid for 3 months prior to Day 0 and no expected
             need for change in dose during study

          -  Forced expiratory volume in 1 second (FEV1) greater than or equal to 80% predicted at
             Screening (Baseline)

          -  18-60 years

          -  General Practitioner diagnosis of asthma of 1 year's minimum duration (with respect to
             Day 0)

          -  No significant abnormality on clinical examination or medical history (excluding
             atopic skin signs, symptoms and history)

          -  12-lead electrocardiogram with no clinical significant abnormality

          -  Clinical chemistry hematology and urinalysis results within the laboratory reference
             ranges or deemed not clinically significant by the Investigator

          -  A negative screen for drugs of abuse and alcohol

          -  Body weight between 50-120 kg

          -  Subjects aged between 18-40 years inclusive must have body mass index (BMI) 18-32
             kilogram per square meter (kg/m^2) inclusive. Subjects aged between 41-60 years must
             have BMI between 18-30 kg/m^2 inclusive.

        Exclusion Criteria:

          -  Active concomitant disease, with exception of eczema

          -  Expected onset of seasonal allergy before the administration of the last dose of study
             medication

          -  History of severe exacerbation within 3 years of Day 0

          -  Recorded use of inhaled short acting beta 2 agonist medication for symptoms within 14
             days of Day 0 of: More than 6 doses per day on any 1 day or more than 3 doses per day
             on 6 or more days

          -  Any medication other than: inhaled short-acting beta 2 agonist, inhaled
             corticosteroids, topic eczema treatments (with the exception of fluorinated
             corticosteroid, dermatological preparations which are not permitted), hormone
             replacement therapy, vitamin preparation/food supplements, occasional use of proton
             pump inhibitors, ranitidine, cimetidine, antacids or over-the-counter analgesics

          -  Treatment within 6 months of Day 0 with any of the following: methylxanthines, inhaled
             cromones, leukotriene modifiers, anti- immunoglobulin E (IgE), anticholinergics,
             ketotifen, oral short acting B2 agonists, long-acting B2 agonists, oral or injected
             corticosteroids

          -  Treatment of atopic symptoms, other than eczema, within 4 weeks of Day 0

          -  History of medication that might carry-over effects into the study

          -  Previously received monoclonal antibody, or a similar related protein, that might
             sensitize to CAT-354

          -  Participation in another study within three months of the start of the study or 5 half
             lives of the previously administered investigational medicinal product (IMP),
             whichever is longer

          -  Lower respiratory tract infection within 4 weeks of Day-14

          -  Any acute illness in the two weeks before Day 0

          -  Current smokers, those who have smoked in previous year, and those with smoking
             history of greater than or equal to 10 pack years

          -  Considered by the investigator to be at risk of transmitting, through blood, the
             agents responsible for infectious diseases

          -  Blood donation (550 ml) in the previous 2 months

          -  Excessive intake of alcohol (more than 21 units a week for females or 28 units a week
             for males)

          -  The subject's general practitioner has suggested a reason the subject should not
             participate in the study

          -  The Investigator considers the subject should not take part for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiltern International Limited</name>
      <address>
        <city>Slough</city>
        <state>Berkshire</state>
        <zip>SL1 2AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010 Jan 8;10:3. doi: 10.1186/1471-2466-10-3.</citation>
    <PMID>20064211</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>March 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2017</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>CAT-354</keyword>
  <keyword>Tralokinumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CAT-354 1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P2">
          <title>CAT-354 5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P3">
          <title>CAT-354 10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant on holiday; unable to attend</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of investigational medicinal product (IMP: CAT-354 or placebo) including those who did not complete the study.</population>
      <group_list>
        <group group_id="B1">
          <title>CAT-354 1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B2">
          <title>CAT-354 5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B3">
          <title>CAT-354 10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="9.07"/>
                    <measurement group_id="B2" value="34.6" spread="7.58"/>
                    <measurement group_id="B3" value="43.3" spread="14.47"/>
                    <measurement group_id="B4" value="40.0" spread="13.04"/>
                    <measurement group_id="B5" value="38.3" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After First Dose</title>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>Pharmacokinetic (PK) population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After First Dose</title>
          <population>Pharmacokinetic (PK) population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>microgram/milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="5.18"/>
                    <measurement group_id="O2" value="156.8" spread="34.55"/>
                    <measurement group_id="O3" value="306.3" spread="31.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Second Dose</title>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 28; Day 35</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Second Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="6.81"/>
                    <measurement group_id="O2" value="161.0" spread="32.81"/>
                    <measurement group_id="O3" value="298.0">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Third Dose</title>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 56; Day 63, 84, 105 and 147</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for CAT-354 After Third Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="4.77"/>
                    <measurement group_id="O2" value="178.7" spread="25.41"/>
                    <measurement group_id="O3" value="393.0">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - t]) for CAT-354 After First Dose</title>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - t]) for CAT-354 After First Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>(mcg*day)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.6" spread="42.03"/>
                    <measurement group_id="O2" value="1691.3" spread="302.70"/>
                    <measurement group_id="O3" value="3106.3" spread="719.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC[0 - Infinity]) for CAT-354 After First Dose</title>
        <description>AUC (0 - infinity) = Area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).</description>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC[0 - Infinity]) for CAT-354 After First Dose</title>
          <description>AUC (0 - infinity) = Area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).</description>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>(mcg*day)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.0" spread="83.33"/>
                    <measurement group_id="O2" value="2314.3" spread="392.91"/>
                    <measurement group_id="O3" value="3861.3" spread="662.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Elimination Phase Half-Life (t[1/2]el) for CAT-354 After First Dose</title>
        <description>Terminal elimination phase half-life is the time measured for the serum concentration to decrease by one half.</description>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Phase Half-Life (t[1/2]el) for CAT-354 After First Dose</title>
          <description>Terminal elimination phase half-life is the time measured for the serum concentration to decrease by one half.</description>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="2.67"/>
                    <measurement group_id="O2" value="16.1" spread="3.60"/>
                    <measurement group_id="O3" value="11.8" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance (CL) for CAT-354 After First Dose</title>
        <description>Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Clearance was normalized by the body weight of the participant.</description>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) for CAT-354 After First Dose</title>
          <description>Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Clearance was normalized by the body weight of the participant.</description>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>(mL/day)/kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.45"/>
                    <measurement group_id="O2" value="2.23" spread="0.46"/>
                    <measurement group_id="O3" value="2.64" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vd) for CAT-354 After First Dose</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Volume of distribution was normalized to the body weight of the participant.</description>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0; Day 4, 7, 14 and 21</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd) for CAT-354 After First Dose</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Volume of distribution was normalized to the body weight of the participant.</description>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="8.04"/>
                    <measurement group_id="O2" value="51.0" spread="10.36"/>
                    <measurement group_id="O3" value="44.0" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After First Dose</title>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After First Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.33"/>
                    <measurement group_id="O2" value="27.1" spread="4.91"/>
                    <measurement group_id="O3" value="40.7">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After Second Dose</title>
        <time_frame>Pre-dose on Day 56</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Drug Concentration for CAT-354 28 Days (C28) After Second Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.63"/>
                    <measurement group_id="O2" value="36.0" spread="11.51"/>
                    <measurement group_id="O3" value="59.4">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Concentration for CAT-354 28 Days (C28) After Third Dose</title>
        <time_frame>Day 84</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Concentration for CAT-354 28 Days (C28) After Third Dose</title>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.99"/>
                    <measurement group_id="O2" value="40.6" spread="12.26"/>
                    <measurement group_id="O3" value="79.6">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 147 that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Day 0 to Day 147</time_frame>
        <population>Safety population included all participants who received at least 1 dose of IMP (CAT-354 or placebo) including those who did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O4">
            <title>Placebp</title>
            <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 147 that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety population included all participants who received at least 1 dose of IMP (CAT-354 or placebo) including those who did not complete the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio (R0) for CAT-354</title>
        <description>Accumulation ratio is calculated as: R0 = AUC(56 - 84)/AUC(0 - 28) where AUC(0 - 28) and AUC(56 - 84) are the area under the serum concentration time curve over a dosage interval determined after the first dose (Day 0 to Day 28) and after the third dose (Day 56 to Day 84), respectively.</description>
        <time_frame>Pre-dose, 10 minutes and 12 hours post-end of infusion on Day 0 and 56; Pre-dose on Day 28; Day 4, 7, 14, 21, 63 and 84</time_frame>
        <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio (R0) for CAT-354</title>
          <description>Accumulation ratio is calculated as: R0 = AUC(56 - 84)/AUC(0 - 28) where AUC(0 - 28) and AUC(56 - 84) are the area under the serum concentration time curve over a dosage interval determined after the first dose (Day 0 to Day 28) and after the third dose (Day 56 to Day 84), respectively.</description>
          <population>PK population included all participants in the safety population for whom sufficient post-dose blood samples were taken to estimate a Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.21"/>
                    <measurement group_id="O2" value="1.39" spread="0.10"/>
                    <measurement group_id="O3" value="1.67">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to 147</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="E2">
          <title>5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="E3">
          <title>10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling hot and cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment to the study was terminated before the planned number of participants was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meena Jain, MB BChir/Associate Medical Director</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>jainm@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

